A European Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
A European Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
This disease registry is a prospective, multicenter non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in participants with HER2-positive unresectable LA/mBC. Diagnosis of unresectable LA or mBC can be up to 6 months old prior to registry enrollment.
Inclusion Criteria:
- Initially diagnosed with HER2-positive unresectable LA/mBC no more than 6 months prior to enrollment, although they can have received anti-cancer treatment during that time
Exclusion Criteria:
- Not applicable
Ried-innkreis, 4910, Austria
Vienna, 1090, Austria
Wiener Neustadt, 2700, Austria
Sofia, 1527, Bulgaria
Palermo, Sicily 90146, Italy
Ancona, The Marches 60121, Italy
Sant'Andrea Delle Fratte (PG), Umbria 06132, Italy
Verona, Veneto 37134, Italy